Figure 6.
LCL161 synergistically enhances the drug efficacy of GEM/CIS in drug-naïve cell lines. (A–M) Dose-response curves for YSCCC, KKU213A, KKU213B, KKU100, HuCCA1, KKU055, HuH28, KKU138, HuCCT1, SSP25, RBE, KKU131, and KKU068 cell lines under LCL161, GEM/CIS, or LCL161 + GEM/CIS treatment. The triplet combination of LCL161 + GEM/CIS was more effective than LCL161 or GEM/CIS treatment. (N) The combination indexes (CIs) of various LCL161 + GEM/CIS combinations generated in RBE, KKU100, HuCCA1, KKU138, KKU131, KKU055, YSCCC, SSP25, HuH28, KKU068, KKU213B, KKU213A, and HuCCT1 cell lines. A CI less than 1 indicates synergism.